Close menu

August 23rd, 2021 | 12:25 CEST

BioNTech, Defence Therapeutics, Dermapharm, NanoRepro - Vaccinate, Test, Treat!

  • Biotechnology
Photo credits:

The vaccination rate in Germany is now just under 59% with complete second vaccination. The Ministry of Health had assumed a 70-80% rate by late summer. The situation has now changed, and the autumn in Germany will likely take place under different conditions. Since the beginning of August, the many travelers returning home have had to undergo a test at the entry border to Germany. Presumably, the number of infections will also rise again, making testing mandatory for social life. Vaccination and testing, therefore, remain ongoing issues for the capital markets.

time to read: 4 minutes | Author: André Will-Laudien

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech - The first profit-taking sets in

    BioNTech shares have been a clear stock market star since their launch in August 2019, with a placement price of USD 20 - last week, the share price reached the USD 400 mark. That makes the Marburg-based Company worth over USD 100 billion. Major shareholders with over 47% are still the Strüngmann brothers. As a result, they rise to number 1 in the German billionaire's list, ahead of the Aldi and Lidl founders.

    After a two-year rally, BioNTech shares began a correction in August. From a high of USD 463, the share price fell to USD 348 by Friday. No disaster, but investors seem to be nervous, especially as reports of possible further side effects are piling up, and the population's willingness to vaccinate is declining. Overall, no big deal for the market leader, in our opinion. Secure your profits with a stop at USD 320 and stay invested.

    Dermapharm on board since 2020

    With the production of the Corona vaccine by BioNTech and its US partner Pfizer, Dermapharm Holding SE is also making an important contribution to the fight against the Corona pandemic. The Company would like to be involved in the development of a COVID drug. To this end, Dermapharm has acquired a stake in a promising player. As part of a capital increase, it is acquiring 24.9% of CORAT Therapeutics GmbH. The Company was launched in May 2020 and reportedly holds several patents of antibodies to treat human infectious diseases. The share price of Dermapharm has already appropriately reacted to the positive news and has risen by 66% since mid-2020 to most recently EUR 76. As a result, the capitalization here has already reached an impressive EUR 4 billion. The slipstream from BioNTech has an extremely inspiring effect here, and the share still has potential.

    Defence Therapeutics - Selection process for AccumTM variants very successful

    It is not only the COVID fight that offers investors opportunities. Recently unveiled, Defence Therapeutics from Canada is a young biotechnology company advancing next-generation vaccines and antibody drug conjugates (ADCs) based on its proprietary Accum platform. Last week, there were new reports on the efficacy of the best AccumTM variants according to the selection process. For this purpose, Defence had tested 43 AccumTM variants conjugated to T-DM1 at a low conjugation ratio (1-4 AccumTM per T-DM1) to identify the best variants for in vitro evaluations. These studies demonstrate the additive effect of AccumTM technology and guide the selection of optimal Accum-T-DM1 in vivo assays in breast and gastric cancer models.

    Among the 43 AccumTM variants tested, the 8 best were selected to be studied in more detail by the Finnish cooperation partner HUS Comprehensive Cancer Center in Helsinki. As a result, the 8 selected Accum-T-DM1 conjugates were able to increase the efficacy of T-DM1 by at least fivefold in the trastuzumab- and T-DM1-resistant HER2 positive breast cancer cell line model called JIMT-1. At a 1.0 ug/ml concentration, T-DM1 induces only about 10% of cytotoxicity compared with Accum-T-DM1 variants, which increase cytotoxicity by 40-70%. The Finnish partner will also carry out a direct comparison with the new ADC Enhertu(R) from AstraZeneca and Daiichi Sankyo.

    The AccumTM platform has been developed and tested in vitro by Defence to enhance intracellular drug delivery in numerous ADCs approved by the US Food and Drug Administration (FDA) or in development. In this regard, Defence has initiated a new study project testing AccumTM variants in the recently developed ADC Enhertu(R) (fam-trastuzumab deruxtecan-nxki) from AstraZeneca and Daiichi Sankyo. Defence's scientific team anticipates that AccumTM will enhance the transport of deruxtecan to the nucleus and significantly enhance the ADC's efficacy. Deruxtecan is an inhibitor that specifically targets the nuclear cell protein topoisomerase I.

    Defence Therapeutics is progressing rapidly and the pipeline is extremely promising. The global immunotherapy market will reach over USD 100 billion in 2021. If DTC succeeds in bringing an innovative product to market, a valuation multiple could occur as early as 2022. One should build the first stocks now.

    NanoRepro - Back in focus

    The share of the Marburg-based test specialist NanoRepro has been back in focus for a few days. The reason is undoubtedly the announcement by some state governments that they will require vacation returnees to be tested in order to detect introduced COVID infections as quickly as possible. The general implementation of the 3G rule for social events, restaurant and stadium visits would lead to a tremendous need for rapid testing.

    NanoRepro recently reported that they had received final approval for two SARS-CoV-2 rapid antigen tests. The rapid antigen and home tests can now be marketed across Europe with the CE mark. According to management statements, EUR 250 million in sales are definitely on the cards for 2021, and EUR 400 million has also already fallen as a contingency. The cash box is already filled with more than EUR 80 million from the last test sales. At a share price of EUR 8, the market capitalization of EUR 120 million is only slightly above the cash value of the share. Six weeks ago, the share was still available below EUR 6; the high was over EUR 22 in March. NanoRepro is a speculative hot revival stock for the late summer.

    The biotech companies presented here address the field of immunization and human therapy in connection with COVID-19. The prices have already risen very sharply but still offer potential. Defence Therapeutics is developing a promising platform that could also be effective in cancer. Those who can achieve success here will create considerable shareholder value.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Stefan Feulner on April 16th, 2024 | 07:40 CEST

    Formycon, Defence Therapeutics, Morphosys - Significant movement in the biotech sector

    • Biotechnology
    • Pharma
    • Cancer

    At the moment, investors are focusing on gold and Bitcoin in addition to the most important indices, like the DAX and Dow Jones. Meanwhile, the biotechnology sector is barely mentioned in the local newspapers. However, the market is on the move, and the wave of takeovers continues unabated. Recently, the Danish pharmaceutical company Genmab announced it was acquiring the private biotech company ProfoundBio for USD 1.8 billion in cash. The acquisition is intended to help deepen the cancer pipeline with next-generation antibody-drug conjugate therapies. Big Pharma is likely to make further acquisitions in this area in the near future.


    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.